We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

3 hedge funds and large institutions have $2.04M invested in Albireo Pharma Inc in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 92 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% less funds holding

Funds holding: 96 → 3 (-93)

99% less capital invested

Capital invested by funds: $396M → $2.04M (-$394M)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 92

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-93
Holders Change %
-96.88%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
92
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$42.3M
2
PA
Perceptive Advisors
New York
-$38M
3
DTC
Deep Track Capital
Connecticut
-$36.8M
4
CC
Chicago Capital
Illinois
-$29.4M
5
BlackRock
BlackRock
New York
-$29.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
26
Endurant Capital Management
California
– -$4.69M -217,209 Closed
Northern Trust
27
Northern Trust
Illinois
– -$3.97M -183,902 Closed
Morgan Stanley
28
Morgan Stanley
New York
– -$3.12M -144,423 Closed
Fiera Capital (Canada)
29
Fiera Capital (Canada)
Quebec, Canada
– -$2.73M -126,109 Closed
BC
30
Birchview Capital
Vermont
– -$2.53M -117,000 Closed
SB
31
Samsara BioCapital
California
– -$2.16M -100,000 Closed
Renaissance Technologies
32
Renaissance Technologies
New York
– -$1.94M -89,683 Closed
Bank of New York Mellon
33
Bank of New York Mellon
New York
– -$1.87M -86,496 Closed
Charles Schwab
34
Charles Schwab
California
– -$1.07M -49,296 Closed
Swiss National Bank
35
Swiss National Bank
Switzerland
– -$921K -42,600 Closed
BGIM
36
Brandywine Global Investment Management
Pennsylvania
– -$911K -42,168 Closed
N
37
Nuveen
North Carolina
– -$870K -40,260 Closed
IBT
38
International Biotechnology Trust
United Kingdom
– -$820K -38,000 Closed
WMSA
39
Weiss Multi-Strategy Advisers
New York
– -$763K -35,322 Closed
Jacobs Levy Equity Management
40
Jacobs Levy Equity Management
New Jersey
– -$652K -30,165 Closed
M&T Bank
41
M&T Bank
New York
– -$638K -29,524 Closed
BC
42
BIT Capital
Germany
– -$602K -27,876 Closed
AllianceBernstein
43
AllianceBernstein
Tennessee
– -$545K -25,200 Closed
Point72 Asset Management
44
Point72 Asset Management
Connecticut
– -$523K -24,200 Closed
PP
45
PDT Partners
New York
– -$510K -23,587 Closed
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
– -$488K -22,599 Closed
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
– -$485K -22,452 Closed
Russell Investments Group
48
Russell Investments Group
United Kingdom
– -$468K -21,662 Closed
SSA
49
Schonfeld Strategic Advisors
New York
– -$397K -18,393 Closed
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
– -$341K -15,802 Closed
1
2
3 4

ALBO Hedge Fund Activity: Q1 2023 in Review

3 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2023, worth a combined $2.04M — down 99% from $396M a quarter earlier.

Sellers outnumbered buyers: 92 funds closed out of ALBO and 0 opened new positions — a net loss of 92 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Federated Hermes, exiting entirely with an estimated $42.3M sold.

  • 3 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2023, down from 96 in Q4 2022.
  • Funds reported $2.04M of Albireo Pharma Inc stock for Q1 2023, down 99% quarter-over-quarter.
  • 0 funds opened new Albireo Pharma Inc positions in Q1 2023 and 92 closed out, a net change of -92 holders.
  • The largest Albireo Pharma Inc seller in Q1 2023 was Federated Hermes, an estimated $42.3M sold.

Based on aggregated 13F filings for Q1 2023.